Circulating miR-192 and miR-193b are markers of prediabetes and are modulated by an exercise intervention

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 3, 2015, Pages E407-E415

  Párrizas, Marcelina ^a,b   Brugnara, Laura ^a,b   Esteban, Yaiza ^a,b   González Franquesa, Alba ^a,b   Canivell, Sílvia ^a,b   Murillo, Serafín ^a,b   Gordillo Bastidas, Elizabeth ^c   Cussó, Roser ^d   Cadefau, Joan A ^d   García Roves, Pablo M ^a,b   Servitja, Joan Marc ^a,b   Novials, Anna ^a,b  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b B R C in D A Metab Dis (Ctro de Invest Biomed en Red de Diabet y Enferm Metab Asociad)   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 125A; MICRORNA 128; MICRORNA 139; MICRORNA 150; MICRORNA 15B; MICRORNA 191; MICRORNA 192; MICRORNA 193B; MICRORNA 21; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; MIRN192 MICRORNA, HUMAN; MIRN193 MICRORNA, HUMAN; TRANSCRIPTOME;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC VALUE; EXERCISE; FATTY LIVER INDEX; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC MARKER; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; HUMAN; IMPAIRED FASTING GLUCOSE; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL VARIABLE; MIDDLE AGED; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS; ANIMAL; BLOOD; C57BL MOUSE; CONTROLLED CLINICAL TRIAL; FEMALE; GENETICS; KINESIOTHERAPY; PHYSIOLOGY; PREDIABETIC STATE;

MUS;

ANIMALS; BIOLOGICAL MARKERS; EXERCISE; EXERCISE THERAPY; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICRORNAS; MIDDLE AGED; PREDIABETIC STATE; TRANSCRIPTOME;

EID: 84924995986     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-2574     Document Type: Article

References (38)

1. Sherwin R, Jastreboff AM. Year in diabetes 2012: the diabetes tsunami. J Clin Endocrinol Metab. 2012;97:4293-4301.
2. Stolar M. Glycemic control and complications in type 2 diabetes mellitus. Am J Med. 2010;123(3 suppl):S3-S11.
3. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
4. Santaguida PL, Balion C, Hunt D, et al. Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose. Evid Rep Technol Assess (Summ). 2005;128:1-11.
5. Hanefeld M, Koehler C, Fuecker K, Henkel E, Schaper F, Temelkova-Kurktschiev T. Insulin secretion and insulin sensitivity pattern is different in isolated impaired glucose tolerance and impaired fasting glucose: the risk factor in Impaired Glucose Tolerance for Atherosclerosis and Diabetes study. Diabetes Care. 2003;26:868-874.
6. DeFronzo RA, Abdul-Ghani M. Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. Am J Cardiol. 2011;108(3 suppl):3B-24B.
7. Silahtaroglu A, Stenvang J. MicroRNAs, epigenetics and disease. Essays Biochem. 2010;48:165-185.
8. Mendell JT, Olson EN. MicroRNAs in stress signaling and human disease. Cell. 2012;148:1172-1187.
9. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18:997-1006.
10. Hunter MP, Ismail N, Zhang X, et al. Detection of microRNA expression in human peripheral blood microvesicles. PLoS One. 2008;3:e3694.
11. Anonymous. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37(suppl 1):S81-S90.
12. Ibañez J, Izquierdo M, Argüelles I, et al. Twice-weekly progressive resistance training decreases abdominal fat and improves insulin sensitivity in older men with type 2 diabetes. Diabetes Care. 2005;28:662-667.
13. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402-408.
14. Bedogni G, Bellentani S, Miglioli L, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33.
15. Rückert IM, Heier M, Rathmann W, Baumeister SE, Döring A, Meisinger C. Association between markers of fatty liver disease and impaired glucose regulation in men and women from the general population: the KORA-F4-study. PLoS One. 2011;6:e22932.
16. Wang K, Yuan Y, Cho JH, McClarty S, Baxter D, Galas DJ. Comparing the microRNA spectrum between serum and plasma. PLoS One. 2012;7:e41561.
17. Calanna S, Scicali R, Di Pino A, et al. Lipid and liver abnormalities in haemoglobin A1c-defined prediabetes and type 2 diabetes. Nutr Metab Cardiovasc Dis. 2014;24:670-676.
18. Zampetaki A, Kiechl S, Drozdov I, et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res. 2010;107:810-817.
19. Pescador N, Perez-Barba M, Ibarra JM, Corbaton A, Martinez-Larrad MT, Serrano-Rios M. Serum circulating microRNA profiling for identification of potential type 2 diabetes and obesity biomarkers. PLoS One. 2013;8:e77251.
20. Ortega FJ, Mercader JM, Moreno-Navarrete JM, et al. Profiling of circulating microRNAs reveals common microRNAs linked to type 2 diabetes that change with insulin sensitization. Diabetes Care. 2014;37:1375-1383.
21. Nielsen LB, Wang C, Sørensen K, et al. Circulating levels of microRNA from children with newly diagnosed type 1 diabetes and healthy controls: evidence that miR-25 associates to residual β-cell function and glycaemic control during disease progression. Exp Diabetes Res. 2012;2012:896362.
22. Zhao C, Dong J, Jiang T, et al. Early second-trimester serum miRNA profiling predicts gestational diabetes mellitus. PLoS One. 2011;6:e23925.
23. Kong L, Zhu J, Han W, et al. Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study. Acta Diabetol. 2011;48:61-69.
24. Rong Y, Bao W, Shan Z, et al. Increased microRNA-146a levels in plasma of patients with newly diagnosed type 2 diabetes mellitus. PLoS One. 2013;8:e73272.
25. Wang YC, Li Y, Wang XY, et al. Circulating miR-130b mediates metabolic crosstalk between fat and muscle in overweight/obesity. Diabetologia. 2013;56:2275-2285.
26. Cantara S, Pilli T, Sebastiani G, et al. Circulating miRNA95 and miRNA190 are sensitive markers for the differential diagnosis of thyroid nodules in a Caucasian population. J Clin Endocrinol Metab. 2014;99:4190-4198.
27. Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of β-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care. 2006;29:1130-1139.
28. Staimez LR, Weber MB, Ranjani H, et al. Evidence of reduced β-cell function in Asian Indians with mild dysglycemia. Diabetes Care. 2013;36:2772-2778.
29. Weyer C, Bogardus C, Pratley RE. Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. Diabetes. 1999;48:2197-2203.
30. Festa A, D'Agostino R Jr, Hanley AJ, Karter AJ, Saad MF, Haffner SM. Differences in insulin resistance in nondiabetic subjects with isolated impaired glucose tolerance or isolated impaired fasting glucose. Diabetes. 2004;53:1549-1555.
31. Nesca V, Guay C, Jacovetti C, et al. Identification of particular groups of microRNAs that positively or negatively impact on β cell function in obese models of type 2 diabetes. Diabetologia. 2013;56:2203-2212.
32. Xiao C, Calado DP, Galler G, et al. MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell. 2007;131:146-159.
33. van de Bunt M, Gaulton KJ, Parts L, et al. The miRNA profile of human pancreatic islets and β-cells and relationship to type 2 diabetes pathogenesis. PLoS One. 2013;8:e55272.
34. Pirola CJ, Fernández Gianotti T, Castaño GO, et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis [published online June 27, 2014]. Gut. doi: 10.1136/gutjnl-2014-306996.
35. Arner E, Mejhert N, Kulyté A, et al. Adipose tissue microRNAs as regulators of CCL2 production in human obesity. Diabetes. 2012;61:1986-1993.
36. Sun L, Xie H, Mori MA, et al. Mir193b-365 is essential for brown fat differentiation. Nat Cell Biol. 2011;13:958-965.
37. Hopper I, Billah B, Skiba M, Krum H. Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta-analysis of randomised controlled clinical trials. Eur J Cardiovasc Prev Rehabil. 2011;18:813-823.
38. Nielsen S, Åkerström T, Rinnov A, et al. The miRNA plasma signature in response to acute aerobic exercise and endurance training. PLoS One. 2014;9:e87308.